Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia.

C Müller-Tidow, P Tschanter, C Röllig, C Thiede, A Koschmieder, M Stelljes, S Koschmieder, M Dugas, J Gerss, T Butterfaß-Bahloul, R Wagner, M Eveslage, U Thiem, S W Krause, U Kaiser, V Kunzmann, B Steffen, R Noppeney, W Herr, C D BaldusN Schmitz, K Götze, A Reichle, M Kaufmann, A Neubauer, Kerstin Schäfer-Eckart (Co-author), M Hänel, R Peceny, N Frickhofen, M Kiehl, A Giagounidis, M Görner, R Repp, H Link, A Kiani, R Naumann, T H Brümmendorf, H Serve, G Ehninger, W E Berdel, U Krug

Research output: Contribution to journalOriginal Articlepeer-review

40 Citations (Web of Science)
Original languageEnglish
Pages (from-to)555-561
JournalLEUKEMIA
Volume30
Issue number3
DOIs
Publication statusPublished - 2016

Keywords

  • CONVENTIONAL CARE REGIMENS
  • ELDERLY-PATIENTS
  • DNMT3A MUTATIONS
  • DNA METHYLATION
  • OPEN-LABEL
  • PHASE-III
  • 5-AZACYTIDINE
  • OUTCOMES
  • RECOMMENDATIONS
  • DECITABINE

Cite this